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Abstract
Despite the discovery more than 15 years ago that patients with hereditary pulmonary arterial hypertension (HPAH) inherit BMP
type 2 receptor (BMPR2) mutations, it is still unclear how these mutations cause disease. In part, this is attributable to the rarity of
HPAH and difficulty obtaining tissue samples from patients with early disease. However, in addition, limitations to the approaches
used to study the effects of BMPR2 mutations on the pulmonary vasculature have restricted our ability to determine how individual
mutations give rise to progressive pulmonary vascular pathology in HPAH. The importance of understanding the mechanisms by
which BMPR2 mutations cause disease in patients with HPAH is underscored by evidence that there is reduced BMPR2 expression
in patients with other, more common, non-hereditary form of PAH, and that restoration of BMPR2 expression reverses established
disease in experimental models of pulmonary hypertension. In this paper, we focus on the effects on endothelial function.
We discuss some of the controversies and challenges that have faced investigators exploring the role of BMPR2 mutations in
HPAH, focusing specifically on the effects different BMPR2 mutation have on endothelial function, and whether there are qualitative
differences between different BMPR2 mutations. We discuss evidence that BMPR2 signaling regulates a number of responses that
may account for endothelial abnormalities in HPAH and summarize limitations of the models that are used to study these effects.
Finally, we discuss evidence that BMPR2-dependent effects on endothelial metabolism provides a unifying explanation for the many
of the BMPR2 mutation-dependent effects that have been described in patients with HPAH.
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BMPR2 mutations and endothelial cell
dysfunction in hereditary pulmonary
arterial hypertension
Hereditary pulmonary arterial hypertension (HPAH) is a
rare disorder that is characterized by progressive, oblitera-
tive remodeling of pre-capillary pulmonary arteries asso-
ciated with increased pulmonary vascular resistance,
ultimately leading to right heart failure and death.1 In
2000, two independent groups reported an association
between heterozygous germline mutations in the bone mor-
phogenetic protein (BMP) type 2 receptor gene, BMPR2,
and cases of autosomal dominant inherited pulmonary
arterial hypertension (PAH).2,3 It is now recognized that
80% of PAH patients with a family history and 20%
of those with no known family history have germline muta-
tions at the BMPR2 locus.4 Since this discovery, germline
mutations have been identified in at least nine other genes in
patients with BMPR2 mutation ‘‘negative’’ HPAH, most
commonly ENDOGLIN and ALK1,5,6 many of which inter-
sect with the BMP signaling pathway and are expressed
at high levels in pulmonary endothelial cells (PECs).5
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The significance of these findings is underscored by the
observation that BMPR2 expression is also reduced in the
lungs of patients with other, non-hereditary idiopathic or
disease-associated forms of PAH,7 and in cultured PECs
from patients with idiopathic PAH (IPAH).8 In addition,
reduced levels of Bmpr2 have been described in a variety
of experimental models of pulmonary hypertension (PH)
that do not involve genetic manipulation of Bmpr2 signal-
ing,9–11 and restoration of Bmpr2 expression or signaling
prevents, and even reverses, established disease in different
experimental models of PH.12–14 These findings suggest that
defects in BMPR2 expression and/or signaling contribute
to common pathophysiological processes in different forms
of PAH. In addition, these findings suggest that the use of
different strategies to enhance BMPR2 expression and/or
function represent promising therapeutic approaches for
the treatment of patients with PAH.15
One of the common features of the pulmonary vascular
pathophysiology in PAH is that there is a hyper-proliferative
phenotype involving diverse cells types including pulmonary
vascular endothelium, smooth muscle, fibroblasts, and
inflammatory cells.16,17 These changes lead to decreased
right ventricular function and, eventually, right heart failure
and death.17 While the primary cellular targets of disease in
patients with IPAH and disease-associated PAH remain to be
established, in HPAH there is good evidence that PECs may
be the primary drivers of disease pathophysiology: PECs
express high levels of BMPR2 in vivo and in vitro,7,18 and
mice with conditional deletion of Bmpr2 restricted to the
endothelium develop spontaneous PH.19
In this review, therefore, we will focus on the role of PEC
dysfunction in mediating BMPR2 mutation-dependent
effects in HPAH. We will discuss some of the controversies
and challenges in this area, focusing specifically on muta-
tion-dependent effects that different BMPR2 mutations may
have on PEC function and susceptibility to HPAH, and
whether there are quantitative and/or qualitative differences
between the effects of different BMPR2 mutations in this
disease. We will review BMPR2-dependent pathways that
may account for abnormalities in PEC function in patients
with HPAH, limitations of the models that are used to study
these effects, and how BMPR2-dependent effects on metab-
olism may be the underlying mechanism mediating BMPR2-
mutation associated PEC dysfunction in HPAH.
Are there genotype-phenotype relationships
between BMPR2 mutations in human HPAH?
Since first described,2,3 more than 380 different genetic vari-
ants across the BMPR2 locus have been identified in
patients with HPAH.5 These mutations occur throughout
the BMPR2 open reading frame and include missense muta-
tions (predicted to give rise to a single amino-acid
exchanges), in-frame exon deletions associated with splice
site mutations (predicted to delete exon segments), as well
as non-sense and frameshift BMPR2 mutations (predicted
to give rise to BMPR2 truncations and/or resulting in loss
of expression of the mutant product as a result of activation
of non-sense mediated messenger RNA [mRNA] decay
[NMD]20). Given the diversity of BMPR2 mutations that
have been described in patients with HPAH, and the fact
that some of these mutant products, when expressed, may
exert additional dominant negative effects on BMPR2 sig-
naling, a number of investigators have sought to determine
whether there are BMPR2 genotype–phenotype associations
that are predictive of disease severity in HPAH. This ques-
tion has been much more difficult to address and the issue is
still debated.
A recent meta-analysis of eight cohorts of patients
with idiopathic, hereditary, and anorexigen-associated
PAH that were systematically tested for BMPR2 mutations
lends support to the hypothesis that all BMPR2 mutations
behave in the same way.4 The main finding of this study
was that BMPR2 mutation-positive PAH patients present
at a younger age and have more severe disease than patients
without mutations. However, the same analysis did not
reveal differences in disease severity between patients with
missense BMPR2 mutations and patients with other
BMPR2 mutations.4 These findings are consistent with an
earlier study which also failed to show differences in disease
severity between HPAH patients carrying missense, truncat-
ing, large rearrangement, or BMPR2 splice site mutations.21
However, two other studies have shown that patients
with truncating mutations predicted to give rise to NMD
have later onset and less severe disease than patients with
BMPR2 mutations that are predicted to give rise to an
expressed mutant product.22,23 These discrepancies may
have resulted from differences in the classification of
the BMPR2 mutations. The two papers showing positive
associations between truncating mutations and improved
outcomes, defined BMPR2 mutations either according to
their NMD status, or by the presence of C-terminal muta-
tions predicted to give rise to NMD.23,24 In contrast, the two
papers that did not report an association between mutation
types and disease severity, compared missense mutations
with all other mutations.4,21 Since the latter includes in-
frame deletions as well as truncating mutations that do
not activate NMD, some of these patients may also express
mutant products that may have dominant inhibitory effects
on BMPR2 function. This problem is confounded by
the observation that some truncating mutations, such as
the BMPR2 W13X mutation, which is predicted to activate
NMD and give rise to a null allele, actually escape NMD
and expresses mutant receptor products.25 Moreover, while
the ability of any mutation to induce NMD can be evaluated
in different cell types (this is often performed in Epstein–
Barr virus transformed lymphocytes for genetic studies in
HPAH22,25), mRNA stability and decay varies between cell
types under different conditions,26 so that the ability of a
given BMPR2 mutation to activate NMD in a particular
target cell in vivo may be impossible to determine (see the
discussion below in relation to PH susceptibility of
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Bmpr2R899X/þ mice12). Given these challenges, it is unlikely
we will be able to answer the question as to whether the
severity of HPAH depends on the type of BMPR2 mutation
from clinical studies alone.
An experimental approach to identify
genotype–phenotype relationships in PH
To address this question, therefore, we have taken an
alternative, experimental approach by evaluating the PH
susceptibility of mice carrying two different germline
Bmpr2 mutations.27 For this, we used two established
mouse lines: Bmpr2Ex4-5/þ mice in which there is an out
of frame deletion of the fourth and fifth exons of Bmpr2
(Bmpr2þ/ mice),28 and Bmpr2Ex2/þ mice in which there
is an in-frame deletion of the second exon of Bmpr2
(Fig. 1a).29 Germline BMPR2 mutations giving rise to
out-of-frame deletions of exons 4 and 5, and in-frame dele-
tions of exon 2, have been described in patients with
HPAH.30 In previous studies, we showed that PECs from
Bmpr2Ex2/þ mice express high levels of the Bmpr2Ex2
mutant allelic product, that this product is abnormally pro-
cessed and retained in the endoplasmic reticulum (ER), and
that chemical chaperones, which enhance maturation of
misfolded proteins in the ER, restore Bmpr2Ex2 protein
expression at the plasma membrane (PM) and enhance
canonical Bmpr2-dependent Smad1/5 signaling in PECs.18
This is illustrated in Fig. 1b in which we use two different
anti-Bmpr2 antibodies to demonstrate that the lower
molecular weight band on Western blot of PEC lysates rep-
resents the Bmpr2Ex2 protein product lacking sequences
encoded by exon 2 of Bmpr2. Moreover, we demonstrated
that cultured lymphocytes from a HPAH patient with a
splice site mutation in the second intron of BMPR2,30 also
express a BMPR2Ex2 mutant receptor that is not properly
trafficked to the PM.18 These findings indicate that
Bmpr2Ex2/þ mice provide a genetic model of a HPAH
BMPR2 mutations that escapes NMD and expresses a
mutant receptor that may exert dominant negative effects
on the remaining wild type (WT) BMPR2 allelic product.
In contrast, Bmpr2þ/ mice provide a genetic model of non-
sense or frameshift HPAH BMPR2 mutations that are sub-
ject to NMD.
We had already shown that Bmpr2Ex2/þ mice have
increased susceptibility to PH in response to prolonged hyp-
oxic exposure when compared with WT littermates.31
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Fig. 1. Characterization of the Bmpr2Ex2 mutant protein product in PECs from Bmpr2Ex2/þ mice. (a) Schematic representation of the Bmpr2
gene. Exons 1–3 encode the extracellular domain of Bmpr2; exon 4 encodes most of the transmembrane domain; exons 5–13 encode the
intracellular kinase domain and C-terminal tail. In-frame deletion of Exon 2 in Bmpr2Ex2/þ mutant mice, and corresponding amino-acid sequences
recognized by the anti-BMPR2 antibodies clone 18 and ASQ, are indicated. (b) Conditionally immortalized PECs (ciPECs) were isolated from WT
control and Bmpr2Ex2/þ mice. These cells were generated, as previously described,18,37,88 by crossing WTor Bmpr2 mutant mice on a C57Bl/6
background with C57Bl/6H-2Kb-tsA58 SV40 large T antigen transgenic mice (Charles River’s ‘‘Immortomouse’’). Primary PECs were isolated
from macerated mouse lungs perfused with trypsin and selected using microvascular endothelial cell medium under permissive conditions (in the
presence of Interferon-g at 33C). For experiments, cells were transferred to 37C without Interferon-g for 3–5 days to inhibit SV40 large T
antigen activity, enabling the cells to become quiescent and differentiate into polarized PECs.18,37,88 Western blot using mouse monoclonal Clone
18 (BD) and ASQ (in house) anti-BMPR2 antibodies in WT and Bmpr2Ex2/þ ciPEC lysates, as described.18 Both cell lines expressed a 150-kDa
WT Bmpr2 product which is detected using both antibodies. Bmpr2Ex2/þ ciPECs also express a 130-kDa product that is detected with Clone 18,
which recognizes a C-terminal peptide sequence that is preserved in both WT Bmpr2 and in the Bmpr2Ex2 mutant product, but not the ASQ
antibody, which recognizes an amino-acid sequence encoded by exon 2. These western blots have not previously been published but similar
studies have been published in Frump et al.18
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This contrasted with previous studies that did not show an
increase in the PH response to prolonged hypoxia in
Bmpr2þ/ mice.32 However, mouse strains affect the severity
of hypoxic PH responses,33 and the two Bmpr2 mutant lines
were maintained on different backgrounds at the time
these studies were performed. Both Bmpr2 mutant lines
were, therefore, back-crossed at least ten generations onto
pure C57BL/6 backgrounds so that we could perform a
direct comparison of PH susceptibility between the two
lines without the confounding influence of the background
stain. We used two experimental models of PH: three weeks
of exposure to 10% oxygen (normobaric hypoxia); and three
weeks of exposure to 10% oxygen in combination with
weekly injections of the non-specific vascular endothelial
growth factor receptor (VEGFR) small molecule inhibitor,
SU5416, as described.34 Consistent with our earlier stu-
dies,31 Bmpr2Ex2/þ mice developed slightly higher right
ventricular systolic pressures (RVSP) compared to WT
and Bmpr2þ/ mice in response to hypoxia alone, but
there was a further increase in RVSPs in Bmpr2Ex2/þ
mice compared with Bmpr2þ/ mice in response to
SU5416 and hypoxia (Fig. 2a and b).27 This was associated
with increased peripheral vessel muscularization, thicken-
ing of the resistance-sized pulmonary arterioles, and reduced
luminal diameters in resistance level arterioles (Fig. 2c–e).27
These findings demonstrated for the first time that there is a
genotype–phenotype relationship between the type of Bmpr2
mutation and PH susceptibility. While limited to experimen-
tal models of PH that do not recapitulate the structural
changes seen in the pulmonary vasculature of patients
B
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Fig. 2. Differential susceptibility of Bmpr2þ/ and Bmpr2Ex2/þ mutant mice to PH. (a, b) Right ventricular systolic pressure (RVSP) measure-
ments in male WT, Bmpr2þ/, and Bmpr2Ex2/þ mutant mice all maintained on a pure C57Bl/6 background (> 10 generations) after exposure to
normoxia or 10% oxygen for three weeks (a) or treatment with the VEGFR2 antagonist, SU5416 (or vehicle) subcutaneously at 20mg/kg
weekly 10% oxygen for three weeks, as indicated (b). RVSP measurements were obtained from pressure traces on right heart catheterization
with Millar Instruments PVR-1035 pressure/volume catheters in anesthetized mice accessed via the right jugular vein. Individual data points
shown, with means SEM indicated. (c) Peripheral muscularization. Lung sections underwent two-color immunofluorescence staining for Von
Willebrand factor and a-SMA. The percent circumference of vessels covered with smooth muscle cells was determined in 20 round or oval
sections of 20–50-mM diameter inter-acinar vessels per mouse. (d) Vessel wall thickness (mean of two orthogonal outer diameter–inner vessel
diameters expressed as the percentage of outer diameter), measured in 10 round or oval sections of 20–50-mM diameter intrapulmonary vessels.
(e) The range of vessel wall thicknesses. Individual data points represent the percentage of total vessels measured in each group with vessel wall
thicknesses within the indicated ranges. One-way ANOVA with Bonferroni correction for between-group comparisons: *P< 0.05; **P< 0.01;
***P< 0.005; #P< 0.0001. Bars indicate statistically significant between group differences. Figure modified from Figs. 2 and 3 in Frump et al. with
permission from the publishers.27
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with established PAH, these studies suggest that different
BMPR2 mutations types could have distinct effects on
PAH severity in HPAH. In support of this hypothesis, a
recent study demonstrated that a mouse with the germline,
heterozygous HPAH-associated C-terminal truncation
mutations, Bmpr2R899X, develops spontaneous PH by the
age of six months.12 The authors also reported that the same
Bmpr2þ/ mice used in our studies did not develop spontan-
eous PH at the same age. However, they also provide evi-
dence that the Bmpr2R899X mutation activates NMD in
pulmonary vascular smooth muscle cells (PVSMCs) from
these mice, suggesting that Bmpr2R899X/þ mice should have
the same PH phenotype as heterozygous null Bmpr2þ/
mutant mice. The fact that Bmpr2R899X/þ mice appear to
have greater susceptibility to PH than Bmpr2þ/ mice, sug-
gests that the Bmpr2R899X mutation escapes NMD in vivo.
Since mRNA stability and decay varies between cell types,26
it is possible that while the Bmpr2R899X mutation is subject
to NMD in cultured PVSMs, it escapes NMD and is
expressed as a mutant protein product in other cell types
in vivo. Since loss of Bmpr2 in endothelium is sufficient to
promote spontaneous PH in mice,19 we would argue that
this is likely to be in the pulmonary endothelium.
Bmpr2 mutation-dependent effects on
pulmonary endothelial cell signaling
and function
Based on our earlier findings that increased susceptibility of
Bmpr2Ex2/þ mice to hypoxic PH was associated with
reduced endothelium-dependent vasodilation of resistance-
sized intrapulmonary arteries,31 we compared levels of acti-
vating serine (S) 1177 and inhibitory threonine (T) 495 endo-
thelial nitric oxide synthase (eNOS) phosphorylation in WT,
Bmpr2þ/, and Bmpr2Ex2/þ mouse lungs. Under basal con-
ditions, there were reduced levels of pS1177 eNOS in both
Bmpr2þ/ and Bmpr2Ex2/þ mouse lungs, associated with a
marked reduction in pT495 eNOS in Bmpr2Ex2/þ but not
Bmpr2þ/ mouse lungs (Fig. 3a and b).27 These effects were
preserved in Bmpr2Ex2/þ but not Bmpr2þ/ mouse lungs
after three weeks of exposure to SU5416 and hypoxia
(Fig. 3c and d). Since persistent de-phosphorylation of
T495 eNOS is associated with eNOS uncoupling,35 these
findings may explain why Bmpr2Ex2/þ mice have reduced
endothelium-dependent vasodilatation in pulmonary vascu-
lature,31 and potentially why Bmpr2Ex2/þ mice have greater
susceptibility to experimental PH.
We have also evaluated alterations in caveolar function
and Src kinase signaling in PECs from the two Bmpr2
mutant lines. As part of our studies to determine the intra-
cellular localization of the Bmpr2Ex2 mutant product in
PECs,18 we evaluated the use of antibodies against caveolin-
1 (Cav-1) and Cavin-1, integral components of caveolae,36
which can be used as PM markers in endothelial cells.
To our surprise, while Cav-1 and Cavin-1 performed well
as PM markers in WT PECs, they performed poorly in
Bmpr2Ex2/þ and Bmpr2þ/ PECs.37 Further analysis of
Bmpr2þ/ PECs showed that this resulted from increased
caveolar endocytosis-associated increased phosphoryl-
ation of tyrosine (Y) 14 Cav-1 and reduced PEC barrier
function.37 Since Src kinase activation regulates pY14
Cav-1-dependent caveolar endocytosis,38 we explored the
role of Src kinase in mediating these effects. Consistent
with previous reports demonstrating increase levels of acti-
vating Y416 phosphorylation of Src kinase in the lungs of
patients with PAH,39,40 Bmpr2þ/ PECs had increased levels
of pY416 Src, and inhibition of Src kinase activity using
small molecule Src family kinase inhibitors PP2 and
SKI606, reduced levels of pY14 Cav-1, decreased caveolar
endocytosis, and improved Bmpr2þ/ PEC barrier function
in vitro.37 However, while our preliminary studies suggested
that there was also increased caveolar endocytosis in
Bmpr2Ex2/þ PECs, unlike Bmpr2þ/ PECs, this is not asso-
ciated with increased pY416 Src in these cells (Fig. 4). While
the mechanisms regulating Src kinase activation in Bmpr2þ/
 PECs remain to be established, these findings suggest that
different mechanisms regulate increased caveolar endocyto-
sis in Bmpr2þ/ and Bmpr2Ex2/þ PECs, and that the two
Bmpr2 mutations have distinct effects on Src kinase activity.
Taken together, our discovery that there are differences in
PEC function and signaling in the two Bmpr2 mouse
mutants illustrates the importance of determining whether
different categories of BMPR2 mutation have distinct effects
on pulmonary vascular cell function. It remains to be deter-
mined whether these differences result from e differences in
Bmpr2 signaling between the two germline Bmpr2mutations
or whether this is a qualitative effect resulting from specific
pathologic properties of the Bmpr2Ex2 mutant allelic
product when expressed in PECs.
Limitations of our current experimental
models of BMPR2 mutation-associated
associated PAH
While Bmpr2Ex2/þ mice develop moderately severe PH in
response to hypoxia and SU5416 (Fig. 2b),27 unlike human
PAH, careful analysis of vessel wall to luminal diameter
ratios in pulmonary resistance vessels did not provide any
evidence that this was associated with obstructive pulmon-
ary vascular remodeling of these vessels (Fig. 2e).27
Furthermore, while changes in endothelial eNOS and Src
kinase activation could account for some of the early
events associated with the development of PAH in patients
carrying BMPR2mutations, they are unlikely to account for
the obstructive vascular remodeling that occurs in patients
with PAH. For example, while mice with eNOS deficiency
develop mild PH associated with muscularization of peri-
acinar pulmonary vessels, they do not develop severe oblit-
erative pulmonary vascular remodeling.41,42 In addition,
while Bmpr2þ/ mice have increased susceptibility to PH
in response to inflammatory challenges and serotonin treat-
ment,43–45 there is no evidence that decreased barrier
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function contributes to the PH phenotype of these mice
and no evidence that any of the germline heterozygous
Bmpr2 mouse mutant lines that have been studied develop
severe obliterative pulmonary vascular remodeling either
spontaneously, with aging, or when exposed to models of
experimental PH.12,27,31,32,43–45 In part, this may be because
we do not yet know how to model the secondary hits (either
genetic or environmental) that are required to induce PAH
in BMPR2 mutation carriers. However, this may also be
because mouse models of PH cannot recapitulate the sever-
ity of the obstructive pulmonary vascular remodeling which
develops over many years in patients with PAH. Rats show
much more robust proliferative and hemodynamic
responses to a variety of different experimentally induced
PH models than mice.46,47 For this reason, there was con-
siderable interest in the development of genetic models of
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Fig. 3. Regulation of eNOS in mouse lungs from WT, Bmpr2þ/, and Bmpr2Ex2/þ mice. (a) Western blots of lung lysates from normoxic mice
demonstrating phosphorylated S1177 and T495 and total eNOS, and -actin. Molecular weight markers indicated. (b) Quantification of band
densities corrected for total eNOS protein, as indicated. (c) Western blots of lung lysates from WT, Bmpr2þ/, and Bmpr2Ex2/þ mice treated
with SU5416 and 10% oxygen for three weeks. (d) Quantification of band densities corrected for total eNOS protein, as indicated. Results
expressed as mean SEM based on western blot data shown normalized to WT normoxic controls. One-way ANOVA with Bonferroni cor-
rection for between-group comparisons: *P< 0.05; **P< 0.01; #P< 0.005, as indicated. (a, b) Modified from Fig. 4 in Frump et al. with permission
from the publishers.27 (c, d) Unpublished data.
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germline Bmpr2 mutations in rats. However, initial reports
indicate that rats carrying two different truncating muta-
tions at the Bmpr2 locus only develop mild spontaneous
and hypoxia-induced PH without evidence of severe oblit-
erative pulmonary vascular remodeling.48,49 An alternative
approach has been to study the effects of conditionally
deleting Bmpr2 expression in different cell types. For exam-
ple, a subset of mice with conditional deletion of Bmpr2 in
endothelial cells develop spontaneous PH associated with
decreased endothelial barrier function, perivascular inflam-
mation, and proliferative vascular remodeling that mimic
some of the features of human PAH.19,50–52 However, pul-
monary vascular remodeling is relatively mild and patchy.
In addition, there is no evidence that complete loss of
BMPR2 (loss of heterozygosity) occurs in vascular lesions
from HPAH patients carrying heterozygous BMPR2 muta-
tions,53 suggesting that complete loss of Bmpr2 expression,
while providing insight into the function of Bmpr2 in the
pulmonary vasculature, may not model the effects that
germline BMPR2 mutations have on the pulmonary vascu-
lature in patients with HPAH. The same maybe said of the
transgenic mouse models that have been developed to over-
express two different HPAH-associated BMPR2 mutations
in different cell types.54–60 While over-expression of mutant
receptors in these mice provides insight into the role of
BMPR2 in regulating the pulmonary vasculature, these
transgenic mice may not model the distinct effects that the
same heterozygous germline mutations have on pulmonary
vascular function in patients with HPAH.
BMPR2-dependent cellular and molecular
pathways promoting PEC dysfunction
Given the limitations of our current in vivo models of
BMPR2 mutation-associated HPAH, we have become
dependent on results of studies, largely based on cell culture
models, that recapitulate some of the observed or inferred
features of established human PAH, without being able to
test the functional significance of these changes directly
using in vivo genetic models that recapitulate the human
disease. Based largely on the analysis of a rat model of
PH in which rats exposed to hypoxia (or unilateral pneu-
monectomy) and treated with SU5416 develop severe PH,
with marked and progressive obstructive pulmonary vascu-
lar remodeling, it has become a widely held view in the PH
research community that one of the early initiating events in
any form of PAH, including BMPR2 mutation-associated
HPAH, is the induction of widespread PEC apoptosis.61–64
This hypothesis goes on to suggest that widespread loss of
endothelial cell integrity is followed by uncontrolled prolif-
erative expansion of surviving pulmonary endothelium,
giving rise to the obliterative neo-intimal proliferation as
well as secondary smooth muscle cell proliferation and peri-
vascular inflammation seen in this rat model and patients
with established PAH.65 In support of this hypothesis, a
number of groups have shown that BMPR2 deficiency in
PECs reduces cell viability by increasing susceptibility to
apoptosis.8,12,66,67 The majority of these studies based their
conclusion on the effects of siRNA knockdown of BMPR2
in PECs. In some cases, these findings were validated in PECs
isolated from IPAH patients (without known BMPR2
mutations),8,66,67 and in one case using blood outgrowth
endothelial progenitor cells from patients with HPAH and
known BMPR2 mutations.12 However, it is notable that
none of these studies explored whether there was a geno-
type-dependent response in PECs from HPAH patients car-
rying different types of BMPR2 mutation and there is, as yet,
no evidence that these effects are sufficient to account for the
obliterative vasculopathy seen in patients with HPAH.
A number of downstream mechanisms have been shown
to mediate these BMPR2-dependent effects on PEC sur-
vival, ranging from abnormalities in BRCA1-dependent
DNA repair67 to activation of canonical Wnt signaling asso-
ciated with reduced Apelin secretion.8 Other studies have
identified BMPR2-dependent effects on Slug and
HMGA1-dependent endothelium to mesenchyme transition
(EndoMT)68 on the expression of chemokines and inflam-
matory cell growth factors by PECs50–52,69 and on increased
production of mitochondrial reactive oxygen species by
PECs.52,56 However, these studies also based their findings
largely on siRNA knockdown or over-expression of HPAH-
associated BMPR2 mutant constructs in PECs. While some
studies were validated in IPAH patient-derived PECs52,69 or
in vivo using mice with conditional deletion of Bmpr2 in
endothelial cells,51,52 limitations of these models means
that we cannot determine the functional significance of
these BMPR2-dependent effects on obliterative vascular
remodeling that is characteristic of HPAH.
Is metabolic reprogramming a common
mediator of BMPR2 mutation effects in PECs?
An investigator reviewing the large number of cell signaling
events that may promote PAH disease susceptibility and
Bmpr2
β-actin
pY416-Src
Total Src
60kDa
60kDa
43kDa
150kDa
Wild type Bmpr2ΔEx2/+ Bmpr2+/-
Fig. 4. Activating Y416 phosphorylation of Src kinase in Bmpr2þ/ but
not Bmpr2Ex2/þ mouse PECs. ciPECs were isolated from WT control,
Bmpr2þ/, and Bmpr2Ex2/þ mice. Western blot using Clone 18 anti-
BMPR2 antibodies, pY416, and total Src kinase, and -actin in WT,
Bmpr2þ/, and Bmpr2Ex2/þ ciPEC lysates, as indicated. Reduced WT
Bmpr2 expression seen in both Bmpr2þ/ and Bmpr2Ex2/þ ciPECs
compared to WT cells. Bmpr2Ex2/þ ciPECs also express a prominent
Bmpr2Ex2 mutant product. pY416 Src kinase is only detected in
Bmpr2þ/ ciPECs. BMPR2 western blot was modified from Fig. 1 in
Frump et al. with permission from the publishers.27 Corresponding
pY416 and total Src kinase western blot studies have not previously
been published.
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PEC dysfunction in mice or humans carrying heterozygous
germline BMPR2 mutations might naturally ask whether
there is a common mechanism mediating these effects or
whether all of these effects could result from interference
with the highly pleotropic actions of a single receptor.
While there is no definitive answer to this question, we
believe that BMPR2-dependent defects in cellular metabol-
ism described in HPAH patients and in cultured PECs with
reduced BMPR2 expression and/or signaling, could account
for diverse BMPR2 mutation-dependent effects in PECs.
A number of studies have shown that there are abnorm-
alities in cellular metabolism, including evidence of reduced
mitochondrial oxidative phosphorylation and increased
glycolytic flux in the right ventricle, pulmonary vasculature,
and in skeletal muscle of patients with PAH and in a variety
of experimental models of PH (reviewed in Sutendra and
Michelakis70). Moreover, treatment with drugs that increase
mitochondrial glucose oxidation, such as the pyruvate
dehydrogenase kinase inhibitor, dichloroacetic acid, which
leads to redirection of glucose metabolism away from lactate
production and towards mitochondrial oxidative metabol-
ism,71 also prevents PH and proliferative vascular remodel-
ing in rat models of monocrotaline (MCT)-induced PH, and
in the Fawn hood rat, a model of spontaneous PH.72–74 This
led to the hypothesis that the proliferative vasculopathy in
PAH results from metabolic reprogramming, reminiscent of
the Warburg effect in cancer. In the classical Warburg effect,
high levels of metabolic intermediates of glycolysis resulting
from increased glycolytic flux, drive the anabolic reactions
that are required for rapid cellular growth.75 As an example
of this, there is evidence of increased glycolysis and reduced
mitochondrial oxidative phosphorylation in isolated PECs
from patients with IPAH, and in vivo, PET imaging data
indicate that there is increased uptake of 18F-fluoro-deoxy
glucose, indicative of increased glucose flux in lungs and
right ventricles of patients with IPAH.76,77 HIF1a, which
is a driver of the metabolic switch from mitochondrial glu-
cose oxidation to glycolysis in cancer,75 may also drive
metabolic reprogramming in IPAH PECs.78
RNA profiling and analysis of metabolic intermediates in
PECs over-expressing PAH-associated BMPR2 mutations
indicate that BMPR2 signaling abnormalities regulate wide-
spread changes in cellular metabolism.79 These studies
demonstrated not only increased glycolysis and reduced
TCA cycle activity, but also upregulation of the pentose
phosphate shunt, along with increased activity of pathways
involved in glutamine and aspartate metabolism in PECs
over-expressing BMPR2 mutant products. In addition,
mitochondrial substrate use is switched from glucose to glu-
tamine in these PECs, and the hyper-proliferative phenotype
of PECs over-expressing HPAH-associated BMPR2 muta-
tions is dependent on glutamine levels in the cell culture
media.80 This effect is also seen in human PAH, in
HIV-associated PH in monkeys, and in MCT-induced PH
in rats, and inhibition of glutaminolysis using glutaminase
inhibitors also prevents proliferative vascular remodeling in
rat MCT PH.80,81 These metabolic changes are likely not
only to affect cellular bioenergetics and growth, but may
also influence diverse cellular functions and signaling
responses. This may be of particular importance in endothe-
lial cells which have relatively low mitochondrial content
and depend largely of glycolysis rather than mitochondrial
glucose oxidation to generate ATP.82 This suggests that the
principal effects of alterations in mitochondrial metabolism
in PECs is not to influence cellular bioenergetics, but rather
to modify other cellular effects of mitochondria on PEC
function. These include: (1) mitochondrial de-polarization
associated with reduced mitochondrial oxidation which
increases sensitivity to apoptosis;83 (2) increased calcium
release resulting from mitochondrial depolarization which
affects calcium-dependent changes in cell function (contrac-
tion, proliferation, and migration), and calcium-dependent
signaling responses;83 (3) alterations in the cellular redox
state resulting from reduced mitochondrial oxidative phos-
phorylation and shunting through the pentose phosphate
pathway, both of which influence physiologic reactive
oxygen species (ROS) signaling and ROS-dependent cellular
pathophysiology;84,85 and (4) changes in the levels of meta-
bolic intermediates which are altered by changes in the
metabolic flux. These changes can have widespread effects
on cell signaling and gene transcription through modifica-
tions in protein phosphorylation (which requires ATP) and
acetylation (which requires acetyl-co-A and is modified by
NAD-dependent deacetylases, Sirtuins, which are regulated
by mitochondrial NAD/NADH levels), and gene regulation
through histone acetylation (which requires acetyl-co-A)
and methylation (histone demethylases are regulated by suc-
cinate/a-ketoglutarate levels).86,87
Taken together, these observations suggest that BMPR2-
associated metabolic reprogramming could explain many of
the observed effects of BMPR2 mutations on PEC function.
However, it remains to be seen whether these changes actu-
ally account for the observed effects of BMPR2 signaling
defects on PEC survival, inflammation, and oxidative
stress, or whether these are sufficient to account for the
marked obliterative vascular remodeling seen in BMPR2
mutation carriers with established HPAH. Furthermore,
we are unaware of any published data in which the effects
of HPAH-associated, heterozygous germline BMPR2 muta-
tions have been evaluated on PEC metabolism. This is
notable not only because of our findings that different
types of BMPR2 mutation may have distinct effects of
PEC function (as discussed above), but also because distinct
effects on PEC metabolism have been described from
BMPR2 siRNA knockdown studies, in which both basal
aerobic glycolysis and mitochondrial glucose oxidation
have been shown to be increased in PECs with reduced
BMPR2 expression.52 This discrepancy between the effects
of BMPR2 siRNA knockdown and BMPR2 mutation over-
expression on PEC metabolism, while not unexpected given
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the differences between the model systems used, does suggest
that there may be quantitative and/or qualitative differences
in PEC metabolism depending on the degree and/or manner
by which BMPR2 signaling is modified. This also suggests
that different types of BMPR2 mutation may have distinct
effects on PEC metabolism.
Summary
In this review, we have focused on the effects that heritable
germ line mutations at the BMPR2 locus have on PEC
function in patients with HPAH. We have discussed both
clinical and experimental evidence for genotype–phenotype
relationships between BMPR2 mutations and disease
severity in HPAH, and how different mutations may have
distinct effects on endothelial cell function. We reviewed
evidence suggesting that BMPR2 signaling defects regulate
a number of different cellular responses that may account
for endothelial abnormalities in HPAH, but also discuss
limitations of the in vitro and in vivo model systems
that have been used to study these effects in the context
of clinically meaningful endpoints. We also summarized
published data indicating that there are widespread
BMPR2-dependent effects on endothelial metabolism that
could provide a unifying explanation for diverse BMPR2
mutation-dependent effects described in patients with
HPAH. Future studies will need to focus on the develop-
ment of more robust in vitro and in vivo experimental
models that will enable us to explore the effects that differ-
ent types of germline BMPR2 mutations have on endothe-
lial cell function, whether these can all be attributed to
effects on endothelial cell metabolism, and ultimately
whether these effects are sufficient to account for the
severe, obliterative pulmonary vascular remodeling that
typically occurs in HPAH patients with established pulmon-
ary vascular disease.
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